The primary objective of this study was to characterize the pharmacokinetics and pharmacodynamics of single daily doses of donepezil (5 and 10 mg) each evening for 28 consecutive days. A secondary objective was to measure the plasma protein binding of donepezil at steady state. Methods This was a double-blind, randomized, multiple-dose study in healthy male (n=13) and female (n=3) volunteers. Subjects were randomized to receive, once daily, either oral doses of 5 mg donepezil for 28 days or doses of 5 mg donepezil for 7 days followed by 10 mg donepezil for 21 days. All doses were administered in the evening. Donepezil concentrations and protein binding in plasma were determined by HPLC with UV detection and equilibrium dialysis, respectively. Inhibition of acetylcholinesterase (AChE) activity in red blood cell (rbc) membranes was assessed using a specific radioenzyme assay. Results The pharmacokinetics of donepezil were linear, dose proportional and stationary over the course of the study. Mean C max , t max , AUC , t D and V lz /F at steady state were 34.1 ng ml −1 , 3.0 h, 634.8 ng h ml −1 , 72.7 h, and 11.8 l kg −1 , respectively, for the 5 mg group and 60.5 ng ml −1 , 3.9 h, 1127.8 ng h ml −1 , 73.5 h and 11.6 l kg −1 , respectively, for the 10 mg group. Accumulation of the drug was observed for 14-21 days, until steady state was achieved. A direct consistent relationship was observed between donepezil plasma concentration and percentage rbc-AChE inhibition during each 24 h evaluation period, indicating no hysteresis in donepezil pharmacodynamics. The pharmacodynamic parameters, E min , E max and E ss , were 62.2%, 71.8% and 65.3%, respectively, for the 5 mg donepezil dose, and 74.7%, 83.6% and 77.8%, respectively, for the 10 mg donepezil dose. Donepezil was 95.6% bound to plasma protein at steady state. The binding was high capacity and low affinity, and neither concentration nor time dependent. Both dosage regimens were well tolerated; no clinically significant changes in laboratory or vital sign parameters were observed in any subject. Conclusions The measured pharmacokinetic and pharmacodynamic parameters for both 5 and 10 mg day −1 donepezil administered in the evening are in good agreement with previous results obtained with morning administration, indicating no time of dosing effect.
Introduction ment on the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog ) [3, 5, 6] . These data support the Donepezil HCl (also known as E2020 or AriceptA, the registered trademark of Eisai Co. Ltd, Tokyo, Japan), a hypothesis that the clinical effect produced by donepezil results from AChE inhibition, with a resultant enhancement chemically distinct and highly selective inhibitor of the enzyme acetylcholinesterase (AChE) [1, 2] has recently been of cholinergic transmission in the CNS. Over 400 000 patient-days of exposure were accumulated approved for marketing in the USA, Canada and several European countries, including the UK, for treatment of the in the pre-registration clinical development programme. The effects of donepezil have also been evaluated during symptoms of mild-moderate Alzheimer's disease.
Results obtained in phase II [3] and phase III [4-6] studies long-term treatment [7, 8] . The findings of an interim analysis of these long-term data show that, compared with demonstrated that donepezil at doses of 5 and 10 mg day was associated with positive therapeutic benefits, as indicated untreated historical control patients, improvements in cognitive and global function achieved during short-term donepeby statistically significant improvements in both cognition and global function. There was also a significant positive zil treatment are sustained at the same level for over 2 years. Other than cholinergically mediated, transient gastrointesticorrelation between the percentage inhibition of AChE nal complaints, there have been no specific adverse events considered likely to be related to donepezil treatment.
evening during clinical trials, no formal study of its protocol. During this period they avoided caffeinecontaining foods or beverages and abstained from physical pharmacokinetics with evening administration had been conducted. This study was designed to characterize the activity other than normal walking. None of the subjects had received any prescription drugs for at least 1 month pharmacokinetics and pharmacodynamics associated with repeated evening administration of single daily doses of 5 or prior to entering the trial. Over-the-counter products and alcohol consumption were prohibited from 72 h prior to 10 mg donepezil. A secondary objective was to measure donepezil plasma protein binding at steady state.
admission until the end of the treatment period.
Methods

Sample collection and analysis
Venous blood samples for analytical determinations were Subjects collected in 7 ml evacuated, heparinized tubes, at the following time-points: 1 h prior to drug administration on Healthy male and female subjects who were 18 years of age or older, and within 20% of ideal weight for their height day 1 and 1, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 18 and 24 h postdose. This same time course for sample collection was and body build based on the Metropolitan Insurance Company Height and Weight Tables (1983) , were eligible repeated on dose administration days 7, 14, 21 and 28 to complete the profile. After the final dose (day 28), additional to enrol in the study. Female subjects were required to be either surgically sterile or a minimum of 2 years samples were collected at 48, 72, 120, 168 and 216 h (day 37). Pre-dose samples were taken immediately prior to post-menopausal.
None of the subjects had clinical evidence of gastrointestidrug administration on all dose administration days. Blood samples for protein binding studies were collected nal, renal, respiratory, endocrine, haematological, neurological, psychiatric or cardiovascular system abnormalities.
in 10 ml, heparinized, evacuated tubes, immediately prior to administration of the final dose (day 28) and at 4, 12, 24, Subjects who had a known or suspected history of alcohol or drug misuse, or a positive urine drug screen, were 72, 120 and 168 h (day 35) afterwards. After collection, the blood samples were centrifuged for excluded from entry, as were those who had donated blood within 1 month of study commencement. Patients who 15 min at 2000 g at 4°C. Plasma was removed, transferred into polypropylene Sarstedt storage tubes and stored in an were smokers or who were taking products containing nicotine were also excluded.
upright position at −20°C until analysis. Following the removal of plasma for donepezil measurements, the white The study was conducted in accordance with the principles stated in the Declaration of Helsinki and the blood cell and platelet layer and the top 3 mm of rbc were removed from the same tube, using a Pasteur pipette. The US Code of Federal Regulations. The study protocol was approved by the Institutional Review Board for remaining rbcs were gently vortexed, transferred into a polypropylene Sarstedt storage tube, and stored in an upright Investigations Involving Human Subjects, Harris Laboratories, Lincoln, Nebraska, USA. All subjects gave position at −20°C until analysis. These cells were used to measure rbc-AChE activity. written informed consent prior to study screening.
Plasma concentrations of donepezil HCl were measured by a specific and sensitive high-performance liquid chromaProtocol tography (HPLC) method with UV detection (315 nm) [9] . The lowest quantifiable concentration was 2 ng ml −1 . This was a randomized, double-blind, multiple-dose study. Subjects were admitted to the study site at least 12 h prior Protein binding was determined by equilibrium dialysis and rbc-AChE activity was measured using a specific and to drug administration. A urine sample for drug screening was collected on admission. Subjects were provided with a sensitive radioenzyme assay [10] , with pre-treatment baseline activity values used to calculate percentage inhibition of standard supper 4 h before dose administration, after which an absolute fast from food and fluids (except water) was activity in post-treatment samples. maintained.
The first dose of donepezil was administered with 250 ml Pharmacokinetic assessments of tap water at 22:00 h. Volunteers remained awake and in an upright position (>45°angle from supine) for 1 h after Non-compartmental pharmacokinetic parameters were computed by standard methods using WinNonlin software dose administration. Fasting continued until the following morning when breakfast was served, 8 h after drug adminis-(version 1.0; Scientific Consultants Inc., Apex, North Carolina, USA). The area under the plasma concentration. After breakfast, the standard meal schedule for the study site was followed. Drug administration continued at tration-time curve from 0 to 24 h (AUC ) was evaluated on days 1, 7, 14, 21 and 28. Plasma concentration data from 22:00 h each evening for an additional 27 days.
Each blinded dose of donepezil consisted of two tablets. days 28-37 were used to calculate the terminal disposition rate constant (l z ) and half-life (t D ), as well as the AUC from To minimize reactions to acute, extensive inhibition of AChE, all subjects initially received one 5 mg donepezil time zero to infinity (AUC (0-2 ) ). The maximum and minimum plasma concentrations tablet and one matching placebo tablet. After 7 days, patients randomized to the 10 mg dose received two 5 mg donepezil achieved in each 24 h observation period (C max and C min , respectively) and the time that C max occurred relative to the tablets for the remaining 21 days of the study.
The subjects stayed at the study centre as in-patients for last dose (t max ) were determined directly from the observed data. The average steady-state concentration of donepezil a total of 37 days in order to ensure compliance with the (C ss ) attained in each subject was estimated as the day 28 binding for each subject was calculated from the values obtained for each of their seven samples. AUC divided by 24. Attainment of steady state was determined by examination of C min , AUC , C max and C ss values.
Safety assessments Total apparent oral clearance (CL T /F) was calculated All adverse events reported spontaneously by the subjects after attainment of steady state by dividing dose by the and/or observed or elicited by questioning during the study product of AUC (0-2 ) and F, a factor that adjusts for systemic were documented together with times of onset and cessation, bioavailability. The apparent volume of distribution ( V lz /F) plus assessments of severity and causality. Vital signs were was calculated as total clearance divided by l z . Both monitored at regular intervals during the entire treatment parameters were adjusted for body weight.
period. The extent of drug accumulation ( R A ) was calculated as the ratio of AUC (0-24) on day 28 relative to that on day 1;
Statistical analysis day 1 values were multiplied by two for the group assigned to receive the 10 mg dose as only the 5 mg dose was ANOVA results were tested for attainment of steady state administered on days 1-7. Normalization of day 28 data to by successive examination of pharmacokinetic parameters 5 mg demonstrated the validity of this day 1 procedure for on days 14, 21 and 28. Statistical models for AUC and estimating R A .
C max included terms for dose, subject (dose), study day and dose×study day. Statistical evaluation of C min was underPharmacodynamic assessments taken using terms for subject and study day. The analysis compared variables on days 14 and 29. Day 29 values were Percentage rbc-AChE inhibition at each time-point was compared with the lowest mean concentrations that occurred calculated from a standard curve fitted to a third-degree between days 14 and 28. polynomial equation [10] . The overall pharmacodynamic Dose proportionality was examined by computing the response was evaluated by integrating percentage rbc-AChE ratio and confidence intervals for least-squares mean estimates inhibition versus time during the 24 h assessment periods of steady-state pharmacokinetic parameters for the 5 and on days 1, 7, 14, 21 and 28 to yield an area under the effect 10 mg doses. curve (AUE ). AUE (0-24) was compared graphically to All statistical calculations were performed on non-log-AUC . E min and E max were taken from the observed transformed data using BioPak software (version 2.1; data. The average percentage rbc-AChE inhibition at steady Scientific Consultants Inc., Apex, North Carolina, USA). state ( E ss ) was computed by integrating percentage rbcAChE inhibition versus time from 0 to 24 h, during the Results 24 h sampling period on day 28, and dividing by 24. The subsequent pharmacodynamic data were examined using a Subject demographics and disposition sigmoidal E max model. Sixteen subjects (13 male and three female), all of whom % AChE inhibition (E t )=[(E max ×C p )/(EC 50 +C p )]×100
were Caucasian, entered this investigation, and 14 completed where E max is the maximal inhibition of AChE, EC 50 is the it. Their ages ranged from 19 to 56 years (mean 38.1 years) concentration of donepezil that reduced AChE activity by and their body weights from 51.4 to 93.0 kg (mean 75.5 kg; 50%, and C p is the measured concentration of donepezil in Table 1 ). The two male subjects, aged 19 and 20 years, who plasma at time t. discontinued the study, did so after 5 days of treatment for personal reasons. As one of these subjects had been randomized to the 5 mg donepezil dose, and the other to Plasma protein binding the 10 mg donepezil dose, there were a total of seven The binding of donepezil to plasma proteins was determined subjects in each donepezil treatment group after their by equilibrium dialysis. This method was selected over withdrawal from the study. ultrafiltration because validation studies demonstrated that donepezil adhered to the ultrafiltration membranes to an Pharmacokinetics extent that prevented accurate analysis. Because the individual data provided no evidence for capacity-limited or Plasma concentration-time curves for the two dose groups are shown in Figure 1 . Plasma concentrations of donepezil concentration-dependent binding in the clinically relevant range of plasma concentrations, the mean percentage protein at steady state were observed to be dose proportional as Figure 2 AUC (0-24) (mean±SD) for both dose levels of Figure 1 Mean (±SE) plasma concentration-time curves for donepezil during the 28 days of drug administration. AUC (0-24) 5 mg and 10 mg donepezil over the course of the 37-day study.
was calculated on days 1, 7, 14, 21 and 28. Full pharmacokinetic profiles were undertaken on days 1, 7, 14, 21 and 28. All other time-points represent trough levels.
10 mg dose level. The difference between the R A values for reflected by C min , C max , C ss and AUC (Table 2) . Dose the two dose groups was not statistically significant. proportionality was demonstrated by the ratios of the leastsquares means for AUC , C max , t max and clearance at steady state for the 5 mg and 10 mg doses, as shown in Pharmacodynamics  Table 3 . The half-life of donepezil averaged 72.7±10.6 h and 73.5±11.8 h for the 5 and 10 mg donepezil doses,
The rbc-AChE inhibition-time curves are shown in Figure 3 and the rbc-AChE inhibition parameters at steady state are respectively, and time-averaged total body clearance was 0.11 l h −1 kg −1 for both donepezil dose groups. Clearance shown in Table 4 . E min was 62.2% and 74.7% and E max was 71.8% and 83.6%, for the 5 mg and 10 mg dose groups, values were unchanged over the course of the study, indicating that the pharmacokinetics of donepezil are respectively. Average rbc-AChE inhibition at steady state ( E ss ) was 65.3% and 77.8% for the 5 mg and 10 mg dose stationary, i.e. there is no evidence of saturation, product inhibition or auto-induction. The large apparent volume of groups, respectively. A significant positive correlation was observed between donepezil plasma concentrations and rbcdistribution (11.8±1.7 and 11.6±1.9 l kg −1 for the 5 and 10 mg donepezil doses, respectively) suggests that donepezil AChE inhibition (Figure 4) . This relationship was consistent during each of the 24-h periods evaluated (days 1, 7, 14, 21 has extensive extravascular distribution. Donepezil accumulated in plasma during the first 2-3 weeks of administration and 28). The relationship of AUEs demonstrates that there were no time-dependent changes in donepezil pharmacodyuntil steady state was achieved (Figure 2) . The mean R A of donepezil was 7.2 at the 5 mg dose level and 6.2 at the namics, such as hysteresis, during this 28-day period ( Figure 5 ). 
Safety
Donepezil was well tolerated by all subjects. The most frequently reported adverse events were headache, gastrointestinal upset, sleep disturbance and lethargy. All were transient, mild and resolved during continued donepezil treatment without the need for adjunctive therapy. The results from this study show that the pharmacokinetics of donepezil are linear and stationary over a 28-day course of once-daily, oral evening administration. interaction studies presented in this supplement.
